Kymera Therapeutics, Inc.
HealthcareNASDAQ:KYMR · NASDAQ Global Market
+$3.25 today
Vol 0.62M · Avg 0.57M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-19.7%
avg -4.4%
ROIC
-20.9%
avg -30.9%
ROA
-17.9%
avg -25.2%
Analysis
ROA is currently the strongest return metric at -17.9% versus its period average of -25.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Nello Mainolfi | Co-Founder, President, Chief Executive Officer & Director | $1.23M | — | 47 | $666,195.00 | 0.81% |
Jared A. Gollob | Chief Medical Officer | $806,344.00 | — | 61 | $117,134.00 | 0.14% |
Bruce N. Jacobs | Chief Financial Officer | $795,250.00 | — | — | $0.00 | <0.01% |
Jeremy G. Chadwick | Chief Operating Officer | $719,400.00 | — | 63 | $44,018.00 | 0.05% |
Noah Goodman | Chief Business Officer | $597,289.00 | — | 39 | $50,195.44 | 0.06% |
Brian R. Adams | Chief Legal Officer & Corporate Secretary | $540,095.00 | — | 52 | $56,625.00 | 0.07% |
Bruce L. Booth DPHIL | Co-Founder & Independent Chairman | $70,000.00 | — | 52 | $0.00 | <0.01% |
Neil Graham MBBS | Chief Development Officer | — | — | 67 | — | — |
Justine E. Koenigsberg | Vice President of Investor Relations | — | — | — | — | — |
Karen Weisbach | Head of People & Culture | — | — | — | — | — |
Juliet Williams | Head of Research | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$172.50M
Sells
111
$78.81M
Net Sentiment
+$93.69M
Net buying
Most Active
Chadwick Jeremy G
29 transactions
1–10 of 113
Analysis
Insiders reported 2 buys worth $172.50M and 111 sells worth $78.81M over the last 12 months. That adds up to net buying of $93.69M. Chadwick Jeremy G was the most active insider with 29 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +151.8% | +20.7% (8yr)9 analysts |
| Net Income | N/A | N/A | N/A | N/A9 analysts |
| EBIT | N/A | N/A | N/A | N/A9 analysts |
Analysis
Recent growth has been strongest in Revenue at +151.8% over three years. Forward estimates point to Revenue at +20.7% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Immunovant, Inc.
NASDAQ:IMVT
$6.90B
Arcellx, Inc.
ACLX
$6.73B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.55B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.34B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ascentage Pharma Group International
NASDAQ:AAPG
$409.04M
Who manages KYMR?
Kymera Therapeutics, Inc. (KYMR) lists 11 active executives. The top listed executive is Brian R. Adams, Chief Legal Officer & Corporate Secretary.
Are KYMR insiders buying or selling?
Recent insider activity shows net buying of $124.18M.
Explore More
Continue the stock analysis
Jump to another research area for this company.